Quarterly Report 2018 Q3

November 20, 2018

An Overview of the Prometic Quarterly Report

  • Extension of maturity dates of Line of Credit and OID Loans to September 2024

  • Implementation of cost control measures to significantly reduce operational burn and extend cash runway

  • Substantial reduction in R&D costs of up to $30 million in 2019 versus 2018

  • Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manufacturing process  

  • Q3 revenues of $12.3 million

  • Granted Rare Pediatric Disease Designation by FDA for PBI-4050 to treat Alström Syndrome

Previous Flipbook
Annual Report 2018
Annual Report 2018

2018 was once again a year filled with strong scientific and clinical program development achievements for ...

Next Flipbook
Quarterly Report Q2 2018
Quarterly Report Q2 2018

Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions rela...